Kornimate/medical-research-clean huggingface dataset:
general practitioners and participation rate in colorectal cancer screening

Conditions: Colorectal Cancer

Summary: colorectal cancer is the 2nd leading cause of cancer mortality in france. however this cancer is preventable in the majority of cases by early detection of adenomas. in france, there is organized colorectal cancer screening, which relies on general practitioners (gps). tests delivered by gps are performed in 89% of cases. however, gps do not systematically offer the test, for time management and communication reasons. patients expect their gps to offer the test and to focus on their expectations. a previous study conducted on gps showed that training in communication and motivational interviewing increases the number of tests performed by 12.2%. in order to facilitate the promotion of screening, the investigators would like to develop a training programme for gps focusing on the application of motivational interviewing (mi) techniques to the promotion of colorectal cancer screening. motivational interviewing is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence. this study is a multicenter trial in general medicine. in this randomized trial the 902 subjects will be included prospectively by the general practitioners (gp) participating in the study. as a first step, general practitioners who have never participated in motivational interviewing training will be recruited and split into 2 groups by randomization, an intervention group and a control group. the interventional group will then undergo a 3 times 2-day training in motivational interviewing. in a second step, the patients will be included by those gp and a self-questionnaire will be send at the inclusion and after 6, 12 and 24 months. the evaluation of the number of tests performed and the analyse of the health belief model (hbm) self-questionnaire will be carried out. at 24 months, there will be an evaluation of the denial motivation questionnaire for patients who have not participated in organized colorectal cancer screening.


Eligibility criteria:
inclusion criteria: * people with an average risk of colorectal cancer (presenting no symptoms or risk factors). * people living in finistère. * people aged 50 to 74 who have never participated in organized screening for colorectal cancer. exclusion criteria: * persons without address to receive the health belief model (hbm)questionnaire * people who do not fit the organized screening criteria * persons unable to give consent (patients under guardianship, curatorship, non-french speaking, illiterate)

Keywords: colorectal cancer general practitioners motivational interviewing
identify the clinical significance and potential implications of peritoneal washing cytology (pwc) in patients with pancreatic cancer

Conditions: Pancreatic Cancer

Summary: pancreatic cancer is a disease with an extremely poor prognosis. such poor results are largely due to a high incidence of local or peritoneal recurrence even after curative r0 resection. if occult microscopic metastasis or residual cancer could be predicted correctly and identify the high risk of peritoneal recurrence, we may have chance to treat these patients by different multimodal locoregional or adjuvant therapy to improve the treatment outcome.

the purpose of this study has three specific aims: (1) to determine the relationship between peritoneal washing cytology (pwc) results and clinicopathologic parameters of pancreatic cancers, (2) to identify the predictive value of pwc and postoperative drainage cytology on the peritoneal recurrence or outcomes, (3) to dissect the molecular mechanism of peritoneal recurrence, especially on the pwc-inducing peritoneal seeding process.

Eligibility criteria:
inclusion criteria: * patients with pancreatic cancers, other non-ductal pancreatic cancers , and benign pancreatic tumors (as negative control population) operated in surgical department after irb proof and receiving patients' informed consent. exclusion criteria: * pregnant women

Keywords: peritoneal washing cytology pancreatic cancer peritoneal metastasis anoikis to determine the relationship between pwc results and clinicopathologic parameters of pancreatic cancers to identify the predictive value of pwc and postoperative drainage cytology on the peritoneal recurrence or outcomes to dissect the molecular mechanism of peritoneal recurrence, especially on the pwc-inducing peritoneal seeding process.
clinical learning study for a mobile smoking cessation program

Conditions: Smoking Cessation; Smoking Behaviors; Smoking Reduction; Smoking, Cigarette; Smoking; Nicotine Dependence

Summary: the purpose of this study are to obtain learnings regarding the digital therapeutic (dtx) experience of clickotine, including acceptability and preference of the overall program and specific dtx components, as well as to obtain learnings related to adult participants' use of the dtx for smoking cessation.


Eligibility criteria:
inclusion criteria: * signed informed consent. * age 18 and older. * for cigarette smokers: smokes at least 5 cigarettes a day. for dual-users: smokes cigarettes and uses e-cigarettes, with the following additional criteria: * smokes at least 5 cigarettes a day * vaping sessions, when they occur, must be for at least 10 minutes (15 puffs) * fluent in written and spoken english (confirmed by ability to read and comprehend the informed consent form) * lives in the united states. * is the solo user of an iphone with iphone operating system (ios)13 or greater capabilities or a smart phone with an android operating system (os) 9 or greater capabilities. * has an active email address. * willing and able to receive sms text messages on their smartphone and email messages. * have access to internet connection during the study duration. * able to confirm download of installed dtx on baseline date. * willing and able to comply with study protocol and assessments. * is willing and able to self-identify sessions of cigarette smoking (1 or more consecutive cigarettes) or vaping (approximately 15 puffs or around 10 minutes in duration) and log those sessions. * self-reported comfort with and ability to use smartphone apps/programs. exclusion criteria: * prior use of clickotine. * currently using a software app for smoking cessation. * lifetime diagnosis of schizophrenia, psychotic disorder, or pervasive developmental disorders, as per participant self-report. * any unstable medical illnesses including hepatic, renal, gastroenterological, respiratory, cardiovascular, endocrine, neurologic (including history of severe head injury with loss of consciousness), immunologic, or hematologic disease, as per participant self-report. * other significant medical condition that, in the opinion of the investigator or study sponsor, may cofound the interpretation of device efficacy, safety, and tolerability. * current use of tobacco-containing products other than cigarettes or e-cigarettes (e.g. snuff, chewing tobacco, cigars, or pipes). * does not have or is unwilling to create a paypal account

Keywords: smoking cessation smoking cessation program smoking cessation digital therapeutic
improving care for patients with high blood pressure

Conditions: Hypertension; Cardiovascular Disease Risk

Summary: the investigators are conducting a single group intervention study to improve blood pressure control and reduce racial and literacy related disparities among people with hypertension. the intervention includes providing patients with home blood pressure monitors, administering phone-coaching to participants, and improving hypertension care at the participating practices from which patients are enrolled. the investigators will follow the patients for 2 years to determine if blood pressure control improves. in addition, the project will explore genetic factors associated with cardiovascular disease risk and treatment success.


Eligibility criteria:
inclusion criteria: * men and women who meet the following inclusion criteria will be eligible for study participation: * 18 years or older, * able and willing to give informed consent, * a current patient of 1 of the 5 participating practices, * have a current diagnosis of hypertension by their primary care physician or have 3 documented blood pressures above 150/90, * their most recent systolic blood pressure was greater than or equal to 150 at their most recent clinic visit, * receive physician approval to participate in the study. * anyone enrolled in the high blood pressure study is eligible to participate in the genomics component of the project. exclusion criteria: * non-english speaking, * current treatment of psychosis, * diagnosed with advanced dementia as determined by the clinician, * current substance abuse, * lack of phone access, * history of malignancy, other than non-melanoma skin cancer, that has not been in remission or cured surgically for \> 5 years, * estimated creatinine clearance less than 30 ml/min (because hypertension management becomes more complicated at this point), * are pregnant.

Keywords: hypertension genomics
intra-articular morphine versus bupivacaine on knee motion in patients with osteoarthritis

Conditions: Analgesia

Summary: context and objective: osteoarthritis causes pain and disability in a high percentage of elderly people. the aim of the present study was to compare the analgesic effect of intra-articular bupivacaine and morphine in patients with knee osteoarthritis. design and setting: a randomized and double-blind study was performed at a pain clinic of são paulo federal university. methods: thirty-nine patients with pain for more than 3 months and an intensity higher than 3 on a numerical scale (zero to 10) were included. g1 patients received 1 mg (1 ml) morphine diluted in 9 ml saline by the intra-articular route, and g2 patients received 25 mg (10 ml) 0.25% bupivacaine without epinephrine. pain was assessed on a numerical scale and knee flexion and extension angles were measured after administration of the drugs at rest and during movement. the total amount of analgesic complementation with 500 mg paracetamol was also determined.

among the 39 patients selected, two patients from group 1 and five from group 2 were excluded from some of the analyses because they did not return on the day of assessment or because they used a complementary analgesic different from that standardized in the study

Eligibility criteria:
inclusion criteria: * older than 50 years with a radiological confirmation of chronic knee osteoarthritis * pain lasting for more than 3 months either at rest or under strain, morning stiffness * absence of heat at the site * crepitation during movement and a pain score ranging from three to ten. exclusion criteria: * patients with coagulopathy * infection or malignant disease * patients who underwent knee or hip surgery; and * patients using opioids 24 hours prior to the study

Keywords: analgesia morphine bupivacaine osteoarthritis knee
phase 2 study of tr-701 in patients with complicated skin and skin structure infections

Conditions: Skin Diseases, Infectious; Skin Diseases, Bacterial

Summary: the purpose of the study is to determine the oral dosage of tr-701 to be used in phase iii studies in patients with complicated skin and skin structure infections.


Eligibility criteria:
inclusion criteria: * diagnosed with complicated skin and skin structure infection with at least 2 signs and symptoms * suspected or confirmed infection due to a gram-positive organism exclusion criteria: * complicated skin and skin structure infection due to gram-negative organisms * complicated skin and skin structure infections requiring more than 7 days of therapy * uncontrolled diabetes * chronic systemic immunosuppressive therapy * aids with cd4 count \< 200 cells/mm3 * uncontrolled hypertension * mild moderate or severe renal failure * severe hepatic disease * neutropenia * use of antidepressants such as ssris or maois for 14 days before first dose of study drug * women who are pregnant or nursing

Keywords: skin infection complicated skin and skin structure infection
cln-0046: treatment of amd subjects with otx-tki

Conditions: Neovascular Age-related Macular Degeneration

Summary: to evaluate the safety, tolerability and efficacy of otx-tki for intravitreal use, in subjects who have neovascular age-related macular degeneration (amd).

a multi-center, dose escalation, phase 1, safety, tolerability and efficacy study to evaluate three dose groups of the otx-tki implant to treat subjects with a diagnosis of primary subfoveal neovascularization secondary to amd.

Eligibility criteria:
inclusion criteria: * are at least 50 years of age * are eligible for standard therapy * have active primary cnvm secondary to amd, either newly diagnosed or previously treated with documented response to anti-vegf therapy in the study eye \[primary subfoveal cnv secondary to amd including juxtafoveal lesions that affect the fovea\] documented by fa and sd-oct * are female who is postmenopausal for at least 12 months prior to screening or surgically sterile; or male or female of childbearing potential willing to use two forms of adequate contraception * are able and willing to comply with all study requirements and visits exclusion criteria: * have previous laser photocoagulation to the center of the fovea in the study eye * have participated in any study involving an investigational drug either in the u.s. or outside the u.s. within the past 30 days * are an employee of the site that is directly involved in the management, administration, or support of the study, or be an immediate family member of the same * have a presence of a disease other than cnvm due to amd in the study eye that could affect vision or safety assessments
celtic bifurcation study

Conditions: Coronary Bifurcations

Summary: this study will examine outcomes for patients treated by planned culotte stenting and compare outcomes with 2 different stent platforms, the next generation synergy ii and the xience xpedition des platforms.


Eligibility criteria:
inclusion criteria: * male or female patient \>18 years old * females of childbearing potential with a negative pregnancy test * coronary artery disease requiring revascularization that is amenable to pci * medina 1,1,1 bifurcation lesion \[13\] with \>70% lesion in both the main vessel and the side branch by visual assessment * main branch and side branch ≥ 2.5mm in diameter by visual assessment * both vessels require stenting in the opinion of the operator exclusion criteria: * acute myocardial infarction with ongoing st-elevation * cardiogenic shock * lesion involves the left main coronary artery * lesion involves bypass graft * plan to treat \>1 other coronary vessel at the time of inclusion * chronic total occlusion of any target vessel * left ventricular ejection fraction \<20% * requirement for ongoing haemodialysis * life-expectancy limited to \<12 months due to co-morbid condition * known allergy to aspirin * known allergy to clopidorel and prasugrel and ticagrelor * known allergy to stent drug elutant * known allergy to any other component of either the synergy ii or xience xpedition stents systems * ongoing participation in another investigational device or drug study * inability to provide informed consent
single follicular dexarelix for lh suppression during ovarian stimulation in oocyte donors.

Conditions: Infertility; Premature Ovarian Failure

Summary: a randomized prospective study in the evaluation of the long acting gnrh antagonist degarelix against the classical multidose regime with ganirelix for lh suppression during the follicular phase of an ovarian stimulation cycle in oocyte donors.

a randomized prospective study of the use of single dose of the long acting gnrh antagonist degarelix for ovarian stimulation cycle in oocyte donors: ovarian stimulation started on cycle day2 with gonadotropins 175-300 iu and either gnrh antagonist single dose degarelix or multidose gnrh antagonist ganirelix initiated on day6 of the stimulation cycle. agonist triggering was used in both groups for oocyte maturation. blastocyst formation rate and live birth rates were estimated for both groups.

Eligibility criteria:
inclusion criteria: * age 20-34 years; * body mass index (bmi) 18-29kg/m2; * regular menstrual cycle of 26-35 days, * amh levels age appropriate (≥2.3 ng/ml) * early follicular- phase serum concentration of fsh within normal limits (1-12 iu/l). exclusion criteria: * women with diabetes and other metabolic disease * women with hereditary genetic diseases; * women with heart disease, qt prolongation,heart failure * elevated liver enzymes, liver failure, hepatitis * women with inflammatory or autoimmune disease * abnormal karyotype; * endometriosis stage iii/iv; * history of recurrent miscarriage; * severe ohss in a previous stimulation cycle or any contraindication for the use of gonadotrophins.

Keywords: antagonist protocol degarelix antagonist protocol degarelix ivf
the randomized double-blind placebo-controlled trial of intralesional botulinum toxin a injection for recalcitrant alopecia totalis and alopecia universalis

Conditions: Recalcitrant Alopecia Totalis; Recalcitrant Alopecia Universalis

Summary: the main purpose of this study is to determine the efficacy of intralesional botulinum toxin type a injection for recalcitrant alopecia totalis and alopecia universalis. treatments of recalcitrant alopecia totalis and universalis remains an challenge issue for medical practice.the application of diphenylcyclopropenone (dpcp) is still being an standard treatment for the condition, however, there are at least thirty percentage of patients recalcitrant to this treatment. the complete etiology of this disease has yet to be clear.nevertheless,recent studies have demonstrated the hypothesis of neurotransmitter involvements. there is numerous evidence in support of an imbalance of transmitters, including substance p and calcitonin gene-related peptide. botulinum toxin a injection has been used to treat a neuralgiform headache and diffused alopecia areata. both headache and hair loss have been made much in improvement. this data may support the neurotransmitter imbalance theory. the investigators have been informed about possible effects to the alopecia condition, therefore, this study is conducted to assess the efficacy of botulinum toxin a as the novel treatment for recalcitrant alopecia totalis and alopecia universalis.


Eligibility criteria:
inclusion criteria: 1. all patients must be over 18 years old 2. all patients are diagnosed with alopecia totalis or alopecia universalis 3. the alopecia condition was not responded to any treatments exclusion criteria: 1. having an active inflammation on scalp area 2. allergic to botulinum toxin a of human albumin 3. has been diagnosed with neuromuscular disorders 4. taking any medication that may interfere with botulinum toxin a action 5. receiving any treatment for alopecia condition within 4 weeks 6. pregnant , breastfeeding, plan to pregnant patients

Keywords: recalcitrant alopecia totalis alopecia universalis botulinum toxin a
chrysalis day program body mass index study

Conditions: Borderline Personality Disorder; Eating Disorders

Summary: this is a study to determine if the approach taken to treat patients in the chrysalis day hospital program will favourably effect their health status as assessed by body mass index (bmi)

as part of the providence continuing care center's continuing quality improvement initiatives this study is to more systematically evaluate the success of the chrysalis day hospital program in dealing with some features of eating disorders commonly experienced by its patients. at intake all clients will be approached to give informed consent to participate. if they do consent they will have their height and weight recorded( if they request they will not be told their weight)as part of the usual intake process conducted by a dietician. when clients exit the program they again will be approached to be weighed. the body mass index will be calculated and compared to admission values. the chrysalis program is a unique day hospital approach to treating individuals with severe personality disorders (primarily borderline)that views the eating disordered behaviour common to these clients as a symptom of many and by addressing core issues of affect dysregulation as well as psychoeducation about eating the eating problems will improve .

Eligibility criteria:
inclusion criteria: * clients of the chrysalis program exclusion criteria: * clients of the chrysalis program who do not consent to the study

Keywords: day hospital treatment
methotrexate single-dose treatment and methotrexate/actinomycin-d single-dose treatment in low-risk gestational trophoblastic neoplasia

Conditions: Gestational Trophoblastic Disease; Gestational Trophoblastic Neoplasia; Gestational Trophoblastic Tumor; Gestational Trophoblastic Neoplasms

Summary: the investigators conducted a trial to determine whether methotrexate or methotrexate/dactinomycin single-course treatment work well as multiple courses of single methotrexate chemotherapy in low-risk gestational trophoblastic neoplasia. it is not yet known whether single-course of chemotherapy is as the same effectiveness as multicourse.


Eligibility criteria:
inclusion criteria: * patients who figo stage i, ii, or iii criteria for low-risk gestational trophoblastic neoplasia (gtn); * who risk score 0-6; * age≤60 years; female, chinese women; * initial treatment is chemotherapy; patients who received prior low-dose methotrexate for treatment of an ectopic pregnancy will be eligible for this study; * performance status: karnofsky score≥60; * laboratory tests: wbc≥3.5×10(9)/l, anc≥1.5×10(9)/l, plt≥80×10(9)/l, serum bilirubin≤ 1.5 times the upper limit of normal, transaminase≤ 1.5 times the upper limit of normal, bun, cr≤ normal * provide written informed consent. exclusion criteria: * patients with unconfirmed diagnosis of gtn; * patients with placental-site trophoblastic tumor (pstt) or epithelioid trophoblastic tumor (ett) * who risk score \>6; * with severe or uncontrolled internal disease, unable to receive chemotherapy; * concurrently participating in other clinical trials * unable or unwilling to sign informed consents; * unable or unwilling to abide by protocol.
ecg monitoring short vs middle term after atrial fibrillation ablation

Conditions: Atrial Fibrillation

Summary: to compare the number of patients with af recurrence detected in a 24-h holter monitoring with a 5-day record.


Eligibility criteria:
inclusion criteria: * have undergone an af ablation procedure at the hospital clínic and have a 12-month follow-up planned. * having been previously assessed by the af nurse. * having signed the informed consent. exclusion criteria: * extreme skin fragility at chest level * allergy to latex or adhesive tape * no electrophysiology follow-up at the clínic hospital. * patients who are already included in other studies that may interfere with the expected results of this one. * patients with cognitive impairment or disorientation.